JPWO2020159754A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020159754A5
JPWO2020159754A5 JP2021544141A JP2021544141A JPWO2020159754A5 JP WO2020159754 A5 JPWO2020159754 A5 JP WO2020159754A5 JP 2021544141 A JP2021544141 A JP 2021544141A JP 2021544141 A JP2021544141 A JP 2021544141A JP WO2020159754 A5 JPWO2020159754 A5 JP WO2020159754A5
Authority
JP
Japan
Prior art keywords
antibody
cdr2
cdr1
optionally
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523710A5 (https=
JP7656330B2 (ja
JP2022523710A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014425 external-priority patent/WO2020159754A2/en
Publication of JP2022523710A publication Critical patent/JP2022523710A/ja
Publication of JP2022523710A5 publication Critical patent/JP2022523710A5/ja
Publication of JPWO2020159754A5 publication Critical patent/JPWO2020159754A5/ja
Application granted granted Critical
Publication of JP7656330B2 publication Critical patent/JP7656330B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544141A 2019-01-28 2020-01-21 Cd44に特異的な抗体 Active JP7656330B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019073402 2019-01-28
CNPCT/CN2019/073402 2019-01-28
PCT/US2020/014425 WO2020159754A2 (en) 2019-01-28 2020-01-21 Antibodies specific to cd44

Publications (4)

Publication Number Publication Date
JP2022523710A JP2022523710A (ja) 2022-04-26
JP2022523710A5 JP2022523710A5 (https=) 2023-02-01
JPWO2020159754A5 true JPWO2020159754A5 (https=) 2023-02-01
JP7656330B2 JP7656330B2 (ja) 2025-04-03

Family

ID=71840370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544141A Active JP7656330B2 (ja) 2019-01-28 2020-01-21 Cd44に特異的な抗体

Country Status (7)

Country Link
US (1) US12311031B2 (https=)
EP (1) EP3917952A4 (https=)
JP (1) JP7656330B2 (https=)
CN (1) CN113474362B (https=)
AU (1) AU2020216780B2 (https=)
TW (1) TWI870378B (https=)
WO (1) WO2020159754A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4350317A4 (en) * 2021-05-28 2024-10-02 NSK Ltd. ROLLING DEVICE STATE DETECTION METHOD, DETECTION DEVICE, AND PROGRAM
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
JP2025535447A (ja) * 2022-10-19 2025-10-24 マルチチュード・セラピューティックス・インコーポレーテッド 抗体-薬物コンジュゲート、その調製方法および使用
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0767378A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Magenkarzinomen
WO2005046597A2 (en) * 2003-11-07 2005-05-26 Brigham And Womens's Hospital, Inc. Antibodies to cd44 glycoforms and uses thereof
US20080171042A1 (en) * 2004-05-07 2008-07-17 University Of Florida Research Foundation, Inc. Cd44 Variants As Therapeutic Targets
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
EP2467491A4 (en) * 2009-08-21 2014-04-02 Sinai School Medicine METHOD OF USE OF CD44 FUSION PROTEINS FOR CANCER TREATMENT
SI3194434T1 (sl) * 2014-09-15 2019-11-29 Molmed Spa Himerni antigenski receptorji
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof
CN108290939B (zh) * 2015-10-16 2023-01-13 纽约市哥伦比亚大学理事会 用于抑制谱系特异性抗原的组合物和方法
AU2017239637A1 (en) * 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN113896793B (zh) * 2021-09-30 2023-05-26 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
JP2021531825A5 (https=)
US20240182542A1 (en) Multi-Specific Molecules
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
AU2018214223B2 (en) Low pH pharmaceutical composition comprising T cell engaging antibody constructs
TWI767899B (zh) Psma及cd3雙特異性t細胞嚙合抗體構築體
JP6959011B2 (ja) Bcmaおよびcd3に対する二重特異性を有するt細胞エンゲージ抗体コンストラクト
JP2021531826A5 (https=)
US20170218078A1 (en) Bispecific t cell engaging antibody constructs
JP2020501531A5 (https=)
CN108136012A (zh) 靶向分子的抗原结合构建体
JPWO2020016662A5 (https=)
JP7611931B2 (ja) ガイダンス及びナビゲーションコントロール(gnc)抗体様タンパク質、その製造方法及び使用方法
TW202233680A (zh) 具有增加的選擇性之多靶向性雙特異性抗原結合分子
JP2025026839A5 (https=)
JP2019512207A5 (https=)
JP2020534012A5 (https=)
JP2020515277A5 (https=)
JPWO2020132190A5 (https=)
JPWO2020159754A5 (https=)
WO2022057875A1 (zh) 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
JPWO2020016661A5 (https=)
JP2026510879A (ja) クローディン18.2に特異的に結合する抗体、その調製方法及びその応用
TW202346368A (zh) 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
JP2023547661A (ja) Cd3に結合するポリペプチド構築物
JPWO2020132232A5 (https=)